Optimal use of current chemotherapy in multimodality therapy for advanced colorectal cancer

Yasuhiro Inoue, Junichiro Hiro, Yuji Toiyama, Koji Tanaka, Yasuhiko Mohri, Masato Kusunoki

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Treatment of advanced colorectal cancer (CRC) increasingly requires a multimodality approach, which adds to the complexity of clinical decision-making. This study investigates the optimal use of current chemotherapy in multi modality therapy for advanced CRC. We enrolled 208 patients with unresectable primary and metastatic (recurrent) CRC who underwent chemotherapy in our hospital. Radiofrequency ablation and/or secondary surgery were used depending on tumor response to chemotherapy. Disease sites varied among patients and included unresectable liver, lung and peritoneal metastasis. Chemotherapy produced cytoreduction in 71 of 208 patients (34%). Multimodality cytoreduction increased overall survival to a median of 46.0 months vs. 20.2 months with chemotherapy alone (P<0.0001). The response rate to chemotherapy was independently associated with cytoreduction. Molecular targeted therapy reduced the number of tumor cells sooner than conventional chemotherapy, and correlated with repeated cytoreduction that further prolonged survival. Aggressive chemotherapy as initial treatment for advanced CRC leads to cytoreduction and is associated with extended survival in patients receiving multimodality therapy.

Original languageEnglish
Pages (from-to)363-368
Number of pages6
JournalOncology Letters
Issue number2
Publication statusPublished - 02-2012
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Optimal use of current chemotherapy in multimodality therapy for advanced colorectal cancer'. Together they form a unique fingerprint.

Cite this